Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms

NCT ID: NCT06787066

Last Updated: 2025-09-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-10

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to assess the interactions between the sympathetic nervous system and the vasculature in women across the menopause transition to better understand why aging women have a higher risk of cardiovascular disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menopause

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Women

Women ages 18-70 years will participate.

Group Type OTHER

Propranolol Hydrochloride

Intervention Type DRUG

Examine how IV propranolol impacts sympathetic transduction

Phentolamine Injection

Intervention Type DRUG

Examine how IV phentolamine impacts sympathetic transduction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propranolol Hydrochloride

Examine how IV propranolol impacts sympathetic transduction

Intervention Type DRUG

Phentolamine Injection

Examine how IV phentolamine impacts sympathetic transduction

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Assigned female at birth
* 18-70 years of age
* Body mass index (BMI) \<30 kg/m2

Exclusion Criteria

* Assigned male at birth
* Pregnancy, breastfeeding
* Body mass index ≥30 kg/m2
* Oral hormonal contraception in last 6 months, history of hormone replacement therapy, oophorectomy
* Current smoking/nicotine use
* Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
* Nerve/neurologic disease
* Cardiovascular, hepatic, renal, respiratory disease
* Blood pressure ≥140/90 mmHg
* Diabetes, Polycystic ovarian syndrome
* Communication barriers
* Prescription medications
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Missouri-Columbia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jacqueline K Limberg, PhD

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Missouri

Columbia, Missouri, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jacqueline Limberg, PhD

Role: CONTACT

573-882-2420

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jacqueline Limberg

Role: primary

573-882-2544

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2125473

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Role of Menopause in Thermoregulation
NCT06798571 RECRUITING PHASE4
Midlife Cholesterol Study
NCT00361075 COMPLETED PHASE4